FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620573669> ?p ?o ?g. }

• W2620573669 endingPage "840" @default.
• W2620573669 startingPage "829" @default.
• W2620573669 abstract "Objective: Conventional antidepressant treatments result in symptom remission in 30% of those treated for major depressive disorder, raising the need for effective adjunctive therapies. Inflammation has an established role in the pathophysiology of major depressive disorder, and minocycline has been shown to modify the immune-inflammatory processes and also reduce oxidative stress and promote neuronal growth. This double-blind, randomised, placebo-controlled trial examined adjunctive minocycline (200 mg/day, in addition to treatment as usual) for major depressive disorder. This double-blind, randomised, placebo-controlled trial investigated 200 mg/day adjunctive minocycline (in addition to treatment as usual) for major depressive disorder. Methods: A total of 71 adults with major depressive disorder ( Diagnostic and Statistical Manual of Mental Disorders–Fourth Edition) were randomised to this 12-week trial. Outcome measures included the Montgomery–Asberg Depression Rating Scale (primary outcome), Clinical Global Impression–Improvement and Clinical Global Impression–Severity, Hamilton Anxiety Rating Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, Social and Occupational Functioning Scale and the Range of Impaired Functioning Tool. The study was registered on the Australian and New Zealand Clinical Trials Register: www.anzctr.org.au , #ACTRN12612000283875. Results: Based on mixed-methods repeated measures analysis of variance at week 12, there was no significant difference in Montgomery–Asberg Depression Rating Scale scores between groups. However, there were significant differences, favouring the minocycline group at week 12 for Clinical Global Impression–Improvement score – effect size (95% confidence interval) = −0.62 [−1.8, −0.3], p = 0.02; Quality of Life Enjoyment and Satisfaction Questionnaire score – effect size (confidence interval) = −0.12 [0.0, 0.2], p < 0.001; and Social and Occupational Functioning Scale and the Range of Impaired Functioning Tool score – 0.79 [−4.5, −1.4], p < 0.001. These effects remained at follow-up (week 16), and Patient Global Impression also became significant, effect size (confidence interval) = 0.57 [−1.7, −0.4], p = 0.017. Conclusion: While the primary outcome was not significant, the improvements in other comprehensive clinical measures suggest that minocycline may be a useful adjunct to improve global experience, functioning and quality of life in people with major depressive disorder. Further studies are warranted to confirm the potential of this accessible agent to optimise treatment outcomes." @default.
• W2620573669 created "2017-06-09" @default.
• W2620573669 creator A5001110294 @default.
• W2620573669 creator A5001792674 @default.
• W2620573669 creator A5016198159 @default.
• W2620573669 creator A5021476541 @default.
• W2620573669 creator A5027165532 @default.
• W2620573669 creator A5032880777 @default.
• W2620573669 creator A5038776015 @default.
• W2620573669 creator A5042151762 @default.
• W2620573669 creator A5050156509 @default.
• W2620573669 creator A5060270013 @default.
• W2620573669 creator A5062932958 @default.
• W2620573669 creator A5068327429 @default.
• W2620573669 creator A5075275032 @default.
• W2620573669 creator A5081907162 @default.
• W2620573669 creator A5091303329 @default.
• W2620573669 date "2017-06-03" @default.
• W2620573669 modified "2023-10-03" @default.
• W2620573669 title "Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial" @default.
• W2620573669 cites W1501527449 @default.
• W2620573669 cites W1521143345 @default.
• W2620573669 cites W1955944566 @default.
• W2620573669 cites W1989563912 @default.
• W2620573669 cites W1991203692 @default.
• W2620573669 cites W1993361478 @default.
• W2620573669 cites W2002519510 @default.
• W2620573669 cites W2004762037 @default.
• W2620573669 cites W2031565182 @default.
• W2620573669 cites W2036717742 @default.
• W2620573669 cites W2042363756 @default.
• W2620573669 cites W2046563865 @default.
• W2620573669 cites W2060345189 @default.
• W2620573669 cites W2065034252 @default.
• W2620573669 cites W2066056481 @default.
• W2620573669 cites W2070147333 @default.
• W2620573669 cites W2081363371 @default.
• W2620573669 cites W2128382881 @default.
• W2620573669 cites W2132324173 @default.
• W2620573669 cites W2151735632 @default.
• W2620573669 cites W2156150528 @default.
• W2620573669 cites W2159126784 @default.
• W2620573669 cites W2216679151 @default.
• W2620573669 cites W2342663112 @default.
• W2620573669 cites W2343957148 @default.
• W2620573669 cites W72255980 @default.
• W2620573669 doi "https://doi.org/10.1177/0004867417709357" @default.
• W2620573669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28578592" @default.
• W2620573669 hasPublicationYear "2017" @default.
• W2620573669 type Work @default.
• W2620573669 sameAs 2620573669 @default.
• W2620573669 citedByCount "72" @default.
• W2620573669 countsByYear W26205736692017 @default.
• W2620573669 countsByYear W26205736692018 @default.
• W2620573669 countsByYear W26205736692019 @default.
• W2620573669 countsByYear W26205736692020 @default.
• W2620573669 countsByYear W26205736692021 @default.
• W2620573669 countsByYear W26205736692022 @default.
• W2620573669 countsByYear W26205736692023 @default.
• W2620573669 crossrefType "journal-article" @default.
• W2620573669 hasAuthorship W2620573669A5001110294 @default.
• W2620573669 hasAuthorship W2620573669A5001792674 @default.
• W2620573669 hasAuthorship W2620573669A5016198159 @default.
• W2620573669 hasAuthorship W2620573669A5021476541 @default.
• W2620573669 hasAuthorship W2620573669A5027165532 @default.
• W2620573669 hasAuthorship W2620573669A5032880777 @default.
• W2620573669 hasAuthorship W2620573669A5038776015 @default.
• W2620573669 hasAuthorship W2620573669A5042151762 @default.
• W2620573669 hasAuthorship W2620573669A5050156509 @default.
• W2620573669 hasAuthorship W2620573669A5060270013 @default.
• W2620573669 hasAuthorship W2620573669A5062932958 @default.
• W2620573669 hasAuthorship W2620573669A5068327429 @default.
• W2620573669 hasAuthorship W2620573669A5075275032 @default.
• W2620573669 hasAuthorship W2620573669A5081907162 @default.
• W2620573669 hasAuthorship W2620573669A5091303329 @default.
• W2620573669 hasConcept C118552586 @default.
• W2620573669 hasConcept C126322002 @default.
• W2620573669 hasConcept C138496976 @default.
• W2620573669 hasConcept C142724271 @default.
• W2620573669 hasConcept C15744967 @default.
• W2620573669 hasConcept C168563851 @default.
• W2620573669 hasConcept C169900460 @default.
• W2620573669 hasConcept C1862650 @default.
• W2620573669 hasConcept C204787440 @default.
• W2620573669 hasConcept C27081682 @default.
• W2620573669 hasConcept C2776000289 @default.
• W2620573669 hasConcept C2777696351 @default.
• W2620573669 hasConcept C2778275353 @default.
• W2620573669 hasConcept C2779177272 @default.
• W2620573669 hasConcept C2779951463 @default.
• W2620573669 hasConcept C2780051608 @default.
• W2620573669 hasConcept C3018162438 @default.
• W2620573669 hasConcept C501593827 @default.
• W2620573669 hasConcept C535046627 @default.
• W2620573669 hasConcept C542102704 @default.
• W2620573669 hasConcept C558461103 @default.
• W2620573669 hasConcept C71924100 @default.
• W2620573669 hasConcept C83849319 @default.

• next